SHZ:300255
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. · SHZ · Healthcare · CNY · FY for 2025
Figures on this page computed 2026-11-08 13:46 UTC
Last close
n/aCNY
Market data
n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CNY
- computed
- Computed from the filing for 2025
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
-40.9%Net margin
Net Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
-7.7%FCF margin
Free Cash Flow / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
1.58Debt/equity
Total Debt / Shareholders' Equity
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
0.7%Dividend yield
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CNY
- computed
Growth is the furthest below its sector's middle: 0.15 against 0.50 on the market's range.
Follow one yuan
lens 1 of 9The five stops
5 of 5 read- After what it costs to make132,413,37315.1%
- After running the business-350,312,893-40.0%
- After interest and tax-357,895,551-40.9%
- After what it must reinvest-67,676,149-7.7%
- Kept after the dividend-186,368,802-21.3%
Of every unit of sales, -0.21 is still there after the dividend.
Of every unit of sales, -0.21 is still there after the dividend.
Every figure in this lens
Except where said otherwise: Computed from the filing for 2025
Sales875,132,346
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- CNY
After what it costs to make132,413,373
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- CNY
After running the business-350,312,893
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- CNY
After interest and tax-357,895,551
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- CNY
After what it must reinvest-67,676,149
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- CNY
Kept after the dividend-186,368,802
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- CNY